News

In other recent news, Alnylam Pharmaceuticals has received approval from the European Commission for its RNAi therapeutic, AMVUTTRA, to treat transthyretin amyloidosis with cardiomyopathy.
Alnylam Pharmaceuticals , a leader in RNA interference (RNAi) therapeutics, is positioning itself for significant growth with the recent approval and launch of its drug Amvuttra for the treatment ...
Additionally, JPMorgan (NYSE: JPM) has maintained an Overweight rating for Alnylam, also setting a price target at $330. The firm anticipates a strong second-quarter performance for AMVUTTRA, ...
Alnylam Pharmaceuticals (NasdaqGS:ALNY) recently announced the appointment of Dr. Pushkal Garg as Executive Vice President and Chief Research and Development Officer to accelerate its R&D efforts ...
Alnylam Pharmaceuticals specializes in RNA interference therapeutics, with Amvuttra being one of its key products targeting transthyretin-mediated amyloidosis, a rare and often fatal disease that can ...
Alnylam has claimed FDA approval for Amvuttra in ATTR cardiomyopathy, allowing it to compete with rival therapies from Pfizer and BridgeBio.
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) is among the best stocks added in a Growth Stock Portfolio.
Alnylam Pharmaceuticals (Nasdaq: ALNY) has won European Commission approval for Amvuttra (vutrisiran) to treat transthyretin ...
Building on the launch of AMVUTTRA ® in transthyretin amyloidosis with cardiomyopathy (ATTR-CM), Alnylam is entering a new phase of growth, and a combined R&D organization will accelerate ...
Alnylam Pharmaceuticals named Pushkal Garg executive vice president and chief research and development officer. The company said Wednesday that Garg will help oversee an integrated R&D ...